Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?
Most patients with congenital von Willebrand disease (VWD) undergoing major surgical procedures require prophylactic replacement therapy with von Willebrand factor (VWF)/factor VIII (FVIII) concentrates. Venous thromboembolism has been reported in such patients, as a result of a combination of various treatments (i.e., type of surgery, progressive increase of post-infusion FVIII plasma levels) and/or patient-related thrombotic risk factors. On the whole, the literature data show that venous thromboembolic complications in surgical VWD patients who have been prophylactically treated with VWF/FVIII concentrates are extremely rare. Indeed, only 11 cases have been reported in the literature, mostly occurring during orthopedic procedures. Thus, in absence of a widely accepted consensus and adequate prospective studies, we advise that the need for thromboprophylaxis in such patients should be evaluated individually, after a careful risk/benefit analysis.
Franchini
Massimo
M
Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliero Universitaria di Parma, Parma, Italy. mfranchini@univr.it
Targher
Giovanni
G
Montagnana
Martina
M
Lippi
Giuseppe
G
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D014842:von Willebrand Diseases / Q000150:complications*; D014841:von Willebrand Factor / Q000009:adverse effects*
D005343:Fibrinolytic Agents; D014841:von Willebrand Factor